Pay in 4 interest-free payments of $5.44 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
4 In TRANSCEND-T2D-1, Lillys first Phase 3 trial in adults with type 2 diabetes (537 participants, 40 weeks), retatrutide produced 16.8% weight loss at the 12 mg dose
However, patients must understand the difference between trial results and approved treatment
:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)
A: Congratulations on your progress so far
Its commercialization for human therapeutic use remains prohibited in France, Europe, and the United States strict research use
Our team of experienced healthcare professionals works closely with you to provide comprehensive care and support throughout your treatment journey
US$ 21.54
US$ 26.43
US$ 27.19
